The data obtained indicate the efficacy of treating patients with COVID-19-associated pneumonia using inhalations of ultra-low doses of MEL as part of therapy, which is supported by a significantly more pronounced clinical effect according to the OSCI, a faster decrease in the intensity of dyspnea, and an anti-inflammatory effect, which was expressed in a faster decrease in the CRP level. Here, CRP is linked to pneumonia.